Abstract
Cancer cells alter their metabolism to support the uninterrupted supply of biosynthetic molecules required for continuous proliferation. Glucose metabolism is frequently reprogrammed in several tumors in addition to fatty acid, amino acid and glutamine metabolism. Pyruvate Dehydrogenase Kinase (PDK) is a gatekeeper enzyme involved in altered glucose metabolism in tumors. There are four isoforms of PDK (1 to 4) in humans. PDK phosphorylates E1α subunit of pyruvate dehydrogenase complex (PDC) and inactivates it. PDC decarboxylates pyruvate to acetyl CoA, which is further metabolized in mitochondria. Overexpression of PDK was observed in several tumors and is frequently associated with chemotherapy related drug resistance, invasion and metastasis. Elevated expression of PDK leads to a shift in glucose metabolism towards glycolysis instead of oxidative phosphorylation. This review summarizes recent literature related to the role of PDKs in cancer and their inhibition as a strategy. In particular, we discuss the role of PDK in tumor progression, metabolic reprogramming in stem cells, and their regulation by miRNAs and lncRNAs, oncogenes and tumor suppressors. Further, we review strategies aimed at targeting PDK to halt tumor growth and progression.
Keywords: Pyruvate dehydrogenase kinase (PDK), cancer, glucose metabolism, PDK regulation, cancer stemness, therapy related resistance, PDK inhibition.
Current Topics in Medicinal Chemistry
Title:Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Volume: 18 Issue: 6
Author(s): Swatishree Sradhanjali and Mamatha M. Reddy*
Affiliation:
- The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Bhubaneswar,India
Keywords: Pyruvate dehydrogenase kinase (PDK), cancer, glucose metabolism, PDK regulation, cancer stemness, therapy related resistance, PDK inhibition.
Abstract: Cancer cells alter their metabolism to support the uninterrupted supply of biosynthetic molecules required for continuous proliferation. Glucose metabolism is frequently reprogrammed in several tumors in addition to fatty acid, amino acid and glutamine metabolism. Pyruvate Dehydrogenase Kinase (PDK) is a gatekeeper enzyme involved in altered glucose metabolism in tumors. There are four isoforms of PDK (1 to 4) in humans. PDK phosphorylates E1α subunit of pyruvate dehydrogenase complex (PDC) and inactivates it. PDC decarboxylates pyruvate to acetyl CoA, which is further metabolized in mitochondria. Overexpression of PDK was observed in several tumors and is frequently associated with chemotherapy related drug resistance, invasion and metastasis. Elevated expression of PDK leads to a shift in glucose metabolism towards glycolysis instead of oxidative phosphorylation. This review summarizes recent literature related to the role of PDKs in cancer and their inhibition as a strategy. In particular, we discuss the role of PDK in tumor progression, metabolic reprogramming in stem cells, and their regulation by miRNAs and lncRNAs, oncogenes and tumor suppressors. Further, we review strategies aimed at targeting PDK to halt tumor growth and progression.
Export Options
About this article
Cite this article as:
Sradhanjali Swatishree and Reddy M. Mamatha*, Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer, Current Topics in Medicinal Chemistry 2018; 18 (6) . https://dx.doi.org/10.2174/1568026618666180523105756
DOI https://dx.doi.org/10.2174/1568026618666180523105756 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Catalytic Organic Reactions on ZnO.
Current Organic Synthesis Translational Optical Imaging in Diagnosis and Treatment of Cancer
Current Pharmaceutical Biotechnology MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review
Current Topics in Medicinal Chemistry Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Subject Index to Volume 1
Current Drug Discovery Technologies Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Editorial (thematic Issue: Functional Performance of L-Carnosine (β-Alanyl-L-Histidine) and Related Imidazole-Containing Dipeptides. Design and Modern Applications of Drug Delivery Systems (Nanosuspensions of Nanosize Materials, Mucoadhesive Drug Delivery Systems, Formulations of Transdermal Patches for Controlled Drug Delivery)
Recent Patents on Drug Delivery & Formulation Identification of Apoptotic Drugs: Multiparametric Evaluation in Cultured Hepatocytes
Current Medicinal Chemistry Pooled RNAi Screens - Technical and Biological Aspects
Current Genomics